Literature DB >> 12485443

Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mice 1.

I Marie1, J L Bény.   

Abstract

We conducted this study to analyze endothelial cell function within intact thoracic aorta of the systemic sclerosis murine model, the heterozygous tight-skin mice 1: (i) assessing the distribution and activation intensity of endothelial cells, responsive to endothelium-dependent vasodilators (acetylcholine, adenosine triphosphate, bradykinin, and substance P) and Iloprost, using laser line confocal microscopy in combination with two Ca2+ fluorescent dyes; (ii) evaluating en-dothelium-dependent vasodilator- and Iloprostinduced relaxation, using isometric tension measurement; and (iii) investigating the role of nitric oxide in mediating relaxation to acetylcholine and adenosine triphosphate. The number of activated endothelial cells was significantly lower in heterozygous tight-skin mice 1, compared with controls, for adenosine triphosphate and Iloprost. Maximal increase of Ca2+ fluorescence intensity ratio in activated endothelial cells was decreased for adenosine triphosphate, bradykinin, and Iloprost, in heterozygous tight-skin mice 1. Adenosine triphosphate- and Iloprost-mediated aortic relaxation was further impaired in heterozygous tight-skin mice 1. Finally, aortic relaxation to acetylcholine and adenosine triphosphate was markedly decreased by nitric oxide synthase inhibitor in heterozygous tight-skin mice 1. This study suggests that endothelial cell receptors for endothelium-dependent vasodilators and Iloprost may not be homogeneously distributed or continuously expressed in thoracic aorta of heterozygous tight-skin mice 1, resulting in endothelium-dependent vasodilatation dysfunction. Moreover, because endothelium-dependent relaxation was highly dependent on nitric oxide release in heterozygous tight-skin mice 1, endothelium-dependent relaxation may differ from that of controls by increased production of nitric oxide. In turn, in heterozygous tight-skin mice 1, the resulting elevated nitric oxide levels may contribute to nitric oxide-mediated free radical endothelial cytotoxicity, although endothelium impairment may be related to other factors, particularly: Fbn-1 gene mutation and transforming growth factor-beta.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485443     DOI: 10.1046/j.1523-1747.2002.19614.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

Review 1.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

2.  High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.

Authors:  Sofia Furtado; Bertrand Dunogué; Georges Jourdi; Benjamin Chaigne; Aziza Chibah; Paul Legendre; Luc Mouthon
Journal:  J Scleroderma Relat Disord       Date:  2020-09-24

3.  Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.

Authors:  Emma C Derrett-Smith; Audrey Dooley; Korsa Khan; Xu Shi-wen; David Abraham; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2010-04-15       Impact factor: 5.156

4.  Vascular alterations upon activation of TGFbeta signaling in fibroblasts--implications for systemic sclerosis.

Authors:  Angelika Horn; Jörg H W Distler
Journal:  Arthritis Res Ther       Date:  2010-06-18       Impact factor: 5.156

Review 5.  Animal models of systemic sclerosis: their utility and limitations.

Authors:  Carol M Artlett
Journal:  Open Access Rheumatol       Date:  2014-07-01

6.  Proteinase activated receptor-2 counterbalances the vascular effects of endothelin-1 in fibrotic tight-skin mice.

Authors:  Fiorentina Roviezzo; Vincenzo Brancaleone; Valentina Mattera Iacono; Antonio Bertolino; Giovanna De Cunto; Valentina Vellecco; Giuseppe Lungarella; Monica Lucattelli; Giuseppe Cirino
Journal:  Br J Pharmacol       Date:  2016-10-05       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.